As­traZeneca, GSK re­it­er­ate 2020 out­look; Shang­hai biotech I-Mab is look­ing for a US part­ner — re­port

→ The coro­n­avirus pan­dem­ic may have thrown off the pre­dictabil­i­ty of what the rest of 2020 will bring for most in­dus­tries, and in­deed many drug­mak­ers, but British bio­phar­ma As­traZeneca stuck by the full-year guid­ance it laid out in Feb­ru­ary and re­port­ed first-quar­ter per­for­mance buoyed by the im­pact of glob­al stock­pil­ing. As ex­pect­ed, the com­pa­ny’s oral drug sales were more re­silient to Covid-19 dis­rup­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER